Date: Tuesday, June 14, 2016
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Halls C&D
Background: Mycophenolic acid (MPA) is a widely used immunosuppressant to prevent acute rejection in kidney transplant recipients (KTRs). However, clinical significance of MPA therapeutic drug monitoring for predicting its efficacy or toxicity have shown inconsistent results. We investigated the correlation of MPA trough concentration (MPA C0) with transplant outcomes and adverse events after kidney transplantation (KT).
Methods: This study included consecutive 70 KTRs who received MPA with tacrolimus and steroid. All the enrolled KTRs prospectively measured MPA C0 which was determined monthly by using particle-enhanced turbidimetric inhibition immunoassay until 12 months and clinical data were collected at each time point. Correlations between MPA dose and MPA C0 were analyzed with Pearson's correlation. Clinical endpoints were biopsy-proven acute rejection (BPAR), graft and patient survival, any cytopenia, severe gastrointestinal symptoms including persistent diarrhea, and severe infections. To determine the effect of MPA C0 on the clinical endpoints, we performed logistic regression analysis in three-divided periods after KT; 0-3, 4-6, and 7-12 months.
Results: MPA C0 was not correlated with MPA dose during the study period (r=0.112, p=0.354). From 0 to 3 month, MPA C0 of patients with leukopenia was significantly higher than that of patients without leukopenia (3.81±0.74 mg/L vs. 2.82±1.13 mg/L; p=0.015). In the same period, MPA C0 was significantly higher in patients with anemia compared to patients without anemia (4.14±1.20 mg/L vs. 2.90±1.09 mg/L, p=0.017). In logistic regression analysis, MPA C0 was associated with leukopenia (OR: 2.65; 95% CI: 1.10- 6.41; p=0.03) and anemia (OR: 2.23; 95% CI: 1.21-4.21; p=0.01). MPA C0 of 3.73 mg/L and 3.00 mg/L best predicted leukopenia and anemia, respectively. However, there were no significant associations of MPA C0 with clinical outcomes including BPAR.
Conclusions: MPA dose was not correlated with MPA C0 in KTRs. High MPA C0 increased the risk of leukopenia and anemia in the early transplant period. Therefore, therapeutic drug monitoring of MPA could be recommended to reduce MPA-related toxicity after KT.
CITATION INFORMATION: Kim C.-D, Cho J.-H, Kim K, Kim M, Do W, Yang Y, Yim T, Hwang I, Lee J.-H, Jung H.-Y, Choi J.-Y, Park S.-H, Kim Y.-L. Clinical Significance of Mycophenolic Acid Therapeutic Drug Monitoring in Kidney Transplant Recipients. Am J Transplant. 2016;16 (suppl 3).
To cite this abstract in AMA style:Kim C-D, Cho J-H, Kim K, Kim M, Do W, Yang Y, Yim T, Hwang I, Lee J-H, Jung H-Y, Choi J-Y, Park S-H, Kim Y-L. Clinical Significance of Mycophenolic Acid Therapeutic Drug Monitoring in Kidney Transplant Recipients. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/clinical-significance-of-mycophenolic-acid-therapeutic-drug-monitoring-in-kidney-transplant-recipients/. Accessed February 28, 2021.
« Back to 2016 American Transplant Congress